拉维生物有限公司是一家领先的农业生物公司，开发基于微生物组、计算驱动的生物刺激剂和生物农药新产品，是 Evogene有限公司，宣布正在扩大其生物杀菌剂的联合验证试验 拜耳公司, a global leader in the agriculture industry, after successful first-year laboratory and greenhouse testing. The tests have demonstrated the efficacy of Lavie Bio’s biofungicides in addressing devastating diseases that affect fruits and vegetables worldwide. Building on these positive outcomes, the companies are progressing to a second year of validation trials in field experiments.
拜耳作物科学生物制品主管 Benoit Hartmann 表示：“这是我们开放式创新战略的重要一步，旨在为种植者带来新的生物解决方案。” “生物杀菌剂是一个真正的创新机会，我们期待与 Lavie Bio 的合作能够帮助我们共同提供新的解决方案。”
“We are delighted with the consistently positive results we have observed in our experiments, which has led to the decision to extend the validation trials for another year in the field,” said 阿米特•诺姆, CEO of Lavie Bio. “This not only highlights the immense business potential of our product and its meaningful impact on farmers worldwide but also reinforces our dedication to collaborative partnerships within the industry as we work together to deliver innovative solutions to the market.”
当农民有效应对可能对作物产量构成重大威胁的疾病的选择有限时，创新农业生物制品，特别是生物杀菌剂的出现，为疾病管理提供了可持续和负责任的方法。这些产品在控制卵菌方面表现出高效，同时最大限度地减少对环境的影响，从而促进可持续农业实践。
Lavie Bio’s commitment to refining its promising bio fungicides through joint validation trials with Bayer AG serves as a powerful testament to the company’s development capabilities, leveraging its innovative BDD platform powered by Evogene’s 微升人工智能 技术引擎。